Vinca alkaloids in combination with inhibitors of EGFR, ERBB2, MEK, for the treatment of mutant Ras-containing tumors.

The current disclosure relates to pharmaceutical combinations useful in the treatment of certain types of cancer. In particular the disclosure relates to the combined use of vinca alkaloid drugs with inhibitors of EGFR/ERB2 and inhibitors of MEK in a triple combination. Ian Bell +31628374976

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More